¼¼°èÀÇ ½º¸¶Æ® Ä¡·á ±â±â ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : ±â±âº°, À¯Å뺰, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)
Smart Therapeutic Devices Market Size, Share & Trends Analysis Report By Devices, By Distribution (Pharmacies, Online Channel, Direct-to-Consumer (DTC)), By End Use (Hospitals, Clinics, Home Care), By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå : 1771508
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 120 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,251,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,638,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,411,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

½º¸¶Æ® Ä¡·á ±â±â ½ÃÀå ¿ä¾à

½º¸¶Æ® Ä¡·á ±â±â ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â 771¾ï 2,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2025³âºÎÅÍ 2030³â±îÁö 12.99%ÀÇ CAGR·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 1,594¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀº ±â¼ú ¹ßÀü, ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡, ¸ÂÃãÇü ÀÇ·á ¹× ÀçÅÃÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù.

ÀÌ·¯ÇÑ ¼ºÀåÀº ±â¼ú ¹ßÀü, ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡, ¸ÂÃãÇü ÀçÅÃÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. ¶ÇÇÑ, Àν¶¸° ÆßÇÁ, ½º¸¶Æ® ÈíÀÔ±â, ½Å°æ ÀÚ±Ø ½Ã½ºÅÛ°ú °°Àº ÈÞ´ë¿ë ¹× Ä¿³ØÆ¼µå µð¹ÙÀ̽ºÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϸ鼭 ƯÈ÷ ´ç´¢º´, õ½Ä, COPD, ½Å°æ Áúȯ µîÀÇ Áúº´ °ü¸® ´É·ÂÀÌ Å©°Ô Çâ»óµÇ°í ÀÖÀ¸¸ç, AI, µ¥ÀÌÅÍ ÃßÀû, ¹«¼± ¿¬°áÀÇ ÅëÇÕÀ¸·Î ½Ç½Ã°£ ¸ð´ÏÅ͸µ, ȯÀÚ Âü¿©, ÀÓ»óÀû ÀÇ»ç°áÁ¤ÀÌ °¡´ÉÇØÁö°í ÀÖ½À´Ï´Ù. ½Ç½Ã°£ ¸ð´ÏÅ͸µ, ȯÀÚ Âü¿©, ÀÓ»óÀû ÀÇ»ç°áÁ¤À» °¡´ÉÇÏ°Ô ÇÏ¿© Ä¡·á ¼º°ú¿Í ȯÀÚ ¼øÀÀµµ¸¦ Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù.

¸¸¼ºÁúȯÀ» °ü¸®Çϱâ À§Çؼ­´Â Áö¼ÓÀûÀÎ °ü¸®°¡ ÇÊ¿äÇϱ⠶§¹®¿¡ ½º¸¶Æ® Ä¡·á ±â±â´Â º´¿ø ¹æ¹®°ú ÀçÅÃÀÇ·áÀÇ °ÝÂ÷¸¦ ÇØ¼ÒÇÏ¿© ±Ã±ØÀûÀ¸·Î »îÀÇ Áú Çâ»ó°ú ÀÔ¿øÀ² °¨¼Ò¿¡ ±â¿©ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¿À¹Ç·Ð ÇコÄɾî´Â 2022³â 7¿ù PSA ±â¼úÀ» »ç¿ëÇÏ¿© ºÐ´ç 5LÀÇ ¼ø»ê¼Ò¸¦ 90% ÀÌ»ó °ø±ÞÇÒ ¼ö ÀÖ´Â ÈÞ´ë¿ë »ê¼Ò¹ß»ý±â¸¦ Ãâ½ÃÇß½À´Ï´Ù. ÀÌ Á¦Ç°Àº ÀçÅà °£È£¿ëÀ¸·Î ¼³°èµÇ¾úÀ¸¸ç, À̵¿¿ë ij½ºÅͰ¡ ÀåÂøµÈ ÄÄÆÑÆ®ÇÏ°í ³»±¸¼ºÀÌ ¶Ù¾î³­ °ÍÀÌ Æ¯Â¡ÀÔ´Ï´Ù.

¶ÇÇÑ, ¸ÂÃãÇü ÀÇ·á Æ®·»µå´Â ½º¸¶Æ® ±â¼úÀÇ Ã¤ÅÃÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 2¿ù Tandem Diabetes Care´Â ³»±¸¼ºÀÌ ¶Ù¾î³­ ¼¼°è ÃÖ¼ÒÇü ÀÚµ¿ Àν¶¸° Åõ¿© ½Ã½ºÅÛÀÎ Tandem Mobi¸¦ Ãâ½ÃÇß½À´Ï´Ù. ÀÌ ¼ÒÇü ¿þ¾î·¯ºí ±â±â´Â iOS¸¦ ÅëÇÑ ¿Ïº®ÇÑ ¸ð¹ÙÀÏ Á¦¾î, ÷´Ü Control-IQ ±â¼ú, Dexcom CGM°úÀÇ È£È¯¼ºÀ» Á¦°øÇϸç, 6¼¼ ÀÌ»óÀÇ »ç¿ëÀÚ¿¡°Ô °³ÀÎÈ­µÈ Àν¶¸° Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.

¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é, 2024³â ÇöÀç ½ÉÇ÷°üÁúȯ, ¾Ï, ´ç´¢º´, ¸¸¼º È£Èí±âÁúȯ µî ºñ°¨¿°¼º Áúȯ(NCDs)Àº Àü ¼¼°è ¿¬°£ »ç¸Á·üÀÇ 74% ÀÌ»óÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ WHO´Â NCDsÀÇ ¿µÇâÀ» °ü¸®ÇÏ°í ¿ÏÈ­Çϱâ À§ÇÑ ºñ¿ë È¿À²ÀûÀÎ Àü·«À¸·Î ¿ø°ÝÀÇ·á ¹× ¸ð¹ÙÀÏ Çコ ±â¼úÀ» Æ÷ÇÔÇÑ µðÁöÅÐ Çコ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ÅõÀÚ È®´ë¸¦ Àû±Ø ÃßÁøÇϰí ÀÖ½À´Ï´Ù. ƯÈ÷ µðÁöÅÐ Çコ °³ÀÔ¿¡ ȯÀÚ 1ÀÎ´ç ¿¬°£ 0.24´Þ·¯¸¸ ÅõÀÚÇØµµ ÇâÈÄ 10³â°£ 200¸¸ ¸í ÀÌ»óÀÇ »ý¸íÀ» ±¸Çϰí 700¸¸ ¸í¿¡ °¡±î¿î ±Þ¼º Áúȯ ¹× ÀÔ¿øÀ» ¿¹¹æÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î ¿¹»óµÇ¸ç, À̸¦ ÅëÇØ Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛ¿¡ °¡ÇØÁö´Â Å« ¾Ð·ÂÀ» ¿ÏÈ­ÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î Àü¸ÁÇϰí ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ ¼¼°è ¿ä±¸¿¡ µû¶ó ÀÇ·á ±â¼ú Á¦°ø¾÷üµéÀº ½º¸¶Æ® Ä¡·á ±â±â Æ÷Æ®Æú¸®¿À¸¦ È®ÀåÇÏ°í ´Ù¾çÈ­Çϰí ÀÖ½À´Ï´Ù. ´ëÇ¥ÀûÀÎ ¿¹·Î GNÀÌ 2025³â 2¿ù Ãâ½ÃÇÑ ¼¼°è ÃÖ¼ÒÇü AI º¸Ã»±âÀÎ ¸®»ç¿îµå ºñºñ¾Æ(ReSound Vivia)¸¦ µé ¼ö Àִµ¥, 1,350¸¸ °³ÀÇ ½ÇÁ¦ ¹®ÀåÀ¸·Î ÇнÀµÈ ÀÌ º¸Ã»±â´Â ½Ã²ô·¯¿î ȯ°æ¿¡¼­ÀÇ ´ëÈ­ ¸í·áµµ¸¦ Å©°Ô Çâ»ó½ÃŰ´Â µ¿½Ã¿¡ ÇÏ·ç Á¾ÀÏ »ç¿ëÇÒ ¼ö ÀÖ´Â ÃÖ´ë 30½Ã°£ÀÇ ÇÏ·ç Á¾ÀÏ »ç¿ëÇÒ ¼ö ÀÖ´Â Àå½Ã°£ ¹èÅ͸®¸¦ Á¦°øÇÕ´Ï´Ù. Áö¿£¸®»ç¿îµå´Â ¶ÇÇÑ ºí·çÅõ½º LE ¿Àµð¿À¿Í Auracast ¹æ¼Û ±â´ÉÀ» °®Ãá °¡Ä¡ Áß½ÉÀÇ Á¦Ç° ¶óÀÎÀÎ ¸®»ç¿îµå »çºñ(ReSound Savvy)¸¦ ¹ßÇ¥Çß½À´Ï´Ù.

COVID-19 »çÅ·ΠÀÎÇØ ÈÞ´ë¿ë »ê¼Ò¹ß»ý±â, ÀΰøÈ£Èí±â µî ½º¸¶Æ® Ä¡·á Àåºñ¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡ÇÏ¿© È£Èí±â ÇÕº´ÁõÀ» °ü¸®ÇÏ´Â µ¥ ÇʼöÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ½º¸¶Æ® ÈíÀÔ±â, Ä¿³ØÆ¼µå ÈíÀÔ±â, COPD °ü¸® µµ±¸´Â È£Èí±âÁúȯ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ °¢±¤À» ¹Þ¾Ò½À´Ï´Ù. ÇÑÆí, Àν¶¸° ÆßÇÁ, ¿þ¾î·¯ºí ÁÖ»ç±â, À̽ÄÇü ¾à¹°Àü´Þ ±â±â´Â ¸¸¼ºÁúȯ ȯÀÚÀÇ º´¿ø ¹æ¹®À» ÁÙÀÌ´Â µ¥ µµ¿òÀÌ µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, COVID-19´Â ¿ø°ÝÀÇ·á ÅëÇÕÀ» ÅëÇÑ ½Å°æ ÀÚ±Ø ¹× û°¢ ÀåºñÀÇ Ã¤ÅÃÀ» ÃËÁøÇß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ºÐ¼® ¹æ¹ý¡¤¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå ½º¸¶Æ® Ä¡·á ±â±â ½ÃÀå : Ä¡·á ±â±â Á¾·ùº° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦5Àå ½º¸¶Æ® Ä¡·á ±â±â ½ÃÀå : À¯Åë ä³Îº° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦6Àå ½º¸¶Æ® Ä¡·á ±â±â ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦7Àå ½º¸¶Æ® Ä¡·á ±â±â ½ÃÀå : Áö¿ªº° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦8Àå °æÀï ±¸µµ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Smart Therapeutic Devices Market Summary

The global smart therapeutic devices market size was estimated at USD 77.12 billion in 2024 and is projected to reach USD 159.42 billion by 2030, growing at a CAGR of 12.99% from 2025 to 2030. This growth is attributed to technological advancements, rising prevalence of chronic diseases, and the growing demand for personalized and home-based care.

This growth is attributed to technological advancements, rising prevalence of chronic diseases, and the growing demand for personalized and home-based care. Moreover, increasing adoption of portable and connected devices-such as insulin pumps, smart inhalers, and neurostimulation systems-has significantly enhanced disease management capabilities, particularly for conditions like diabetes, asthma, COPD, and neurological disorders. The integration of AI, data tracking, and wireless connectivity enables real-time monitoring, patient engagement, and clinical decision-making, thereby improving treatment outcomes and patient adherence.

With chronic disease management requiring continuous care, smart therapeutic devices bridge the gap between hospital visits and home-based healthcare, ultimately contributing to improved quality of life and reduced hospitalization rates. For instance, in July 2022, OMRON Healthcare launched a portable oxygen concentrator delivering 5L/min of >90% pure oxygen using PSA technology. Designed for home care, it features a compact, durable design with caster wheels for mobility.

Moreover, the trend toward personalized medicine continues to accelerate the adoption of smart technologies. For instance, in February 2024, Tandem Diabetes Care launched Tandem Mobi, the world's smallest durable automated insulin delivery system. This compact, wearable device offers full iOS mobile control, advanced Control-IQ technology, and compatibility with Dexcom CGMs, enabling personalized insulin therapy for users aged six and up.

According to the World Health Organization (WHO), as of 2024, noncommunicable diseases (NCDs) such as cardiovascular diseases, cancer, diabetes, and chronic respiratory conditions account for over 74% of global mortality annually. In response, the WHO is actively promoting greater investment in digital health solutions-including telemedicine and mobile health technologies-as a cost-effective strategy to manage and mitigate the impact of NCDs. Notably, an investment of merely USD 0.24 per patient per year in digital health interventions is projected to save over 2 million lives and prevent nearly 7 million acute events and hospitalizations over the next decade, thereby alleviating significant pressure on global healthcare systems.

These global imperatives are driving healthcare technology providers to expand and diversify their smart therapeutic device portfolios. A key example is GN's February 2025 launch of ReSound Vivia, touted as the world's smallest AI-powered hearing aid. Trained on 13.5 million real-world sentences, the device significantly enhances speech clarity in noisy environments while offering extended battery life of up to 30 hours for all-day use. GN also introduced ReSound Savi, a value-driven product line featuring Bluetooth LE Audio and Auracast broadcast capabilities-further democratizing access to advanced hearing solutions and aligning with global digital health priorities.

The COVID-19 pandemic significantly increased the demand for smart therapeutic devices like portable oxygen concentrators and ventilators became critical for managing respiratory complications. Smart inhalers, connected inhalers, and COPD management tools gained prominence due to the rise in respiratory illness awareness. On the other hand, insulin pumps, wearable injectors, and implantable drug delivery devices helped reduce hospital visits for chronic disease patients. The pandemic also pushed the adoption of neurostimulation and hearing devices through telehealth integration.

Global Smart Therapeutic Devices Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global smart therapeutic devices market report based on devices, distribution, end use and regions.

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Market Variables, Trends, & Scope

Chapter 4. Smart Therapeutics Devices Market: Therapeutic Devices Type Estimates & Trend Analysis

Chapter 5. Smart Therapeutics Devices Market: Distribution Channel Estimates & Trend Analysis

Chapter 6. Smart Therapeutics Devices Market: End Use Estimates & Trend Analysis

Chapter 7. Smart Therapeutics Devices Market: Regional Estimates & Trend Analysis

Chapter 8. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â